PD
PLRX icon

Point72 (DIFC)’s Pliant Therapeutics PLRX Stock Holding History

Point72 (DIFC)’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$166 Sell
112
-6,996
-98% -$10.7K ﹤0.01% 1106
2025
Q2 		$8.24K Buy
+7,108
New +$10K ﹤0.01% 1337

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 (DIFC)'s PLRX Position: Q3 2025 in Review

Point72 (DIFC) reduced its Pliant Therapeutics (PLRX) stake by 98% in Q3 2025, selling an estimated $10.7K and leaving 112 shares worth $166. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Point72 (DIFC) first reported a position in PLRX in Q2 2025 and has held it in 2 quarters since. The position peaked at $8.24K in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Point72 (DIFC) held 112 shares of Pliant Therapeutics worth $166 as of Q3 2025.
  • Point72 (DIFC) sold 6,996 Pliant Therapeutics shares in Q3 2025, an estimated $10.7K.
  • Pliant Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1106 holding.
  • Point72 (DIFC) first reported a position in Pliant Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Pliant Therapeutics position peaked at $8.24K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.